September 9, 2025 – Basel – In a move set to strengthen its cardiovascular disease portfolio, Novartis announced an agreement to acquire Tourmaline Bio (Nasdaq: TRML) for approximately USD 1.4 billion. The acquisition brings into Novartis’ pipeline pacibekitug, a Phase 3-ready investigational anti-IL-6 monoclonal antibody with the potential to transform treatment for atherosclerotic cardiovascular disease (ASCVD), the world’s leading cause of death.
Science Significance
Pacibekitug represents a promising breakthrough in cardiovascular medicine, targeting systemic inflammation, a recognized but unmet driver of ASCVD risk. Data from the Phase 2 TRANQUILITY trial demonstrated that pacibekitug reduced hs-CRP levels by up to 86% over 90 days, with safety comparable to placebo. Unlike conventional lipid-lowering drugs, pacibekitug works through IL-6 inhibition, addressing residual inflammatory risk that persists despite standard therapies. This novel mechanism of action positions pacibekitug as a potential first-in-class therapy in cardiovascular inflammation.
Regulatory Significance
The deal underscores the importance of accelerating late-stage assets into Phase 3 programs, with regulatory submissions anticipated if pivotal trials confirm efficacy and safety. ASCVD remains a high-priority area for regulators worldwide due to its global mortality burden, and therapies with strong biomarker reductions such as hs-CRP may be positioned for expedited pathways. Novartis’ global regulatory infrastructure provides a strong foundation to advance pacibekitug toward approval.
Business Significance
Advertisement
Novartis’ USD 1.4 billion cash acquisition of Tourmaline Bio highlights the strategic value of cardiovascular innovation. By paying USD 48 per share, Novartis gains a late-stage biologic asset that complements its cardiology portfolio alongside lipid and RNA-targeted therapies. The move also diversifies Novartis’ cardiovascular pipeline beyond genetics and lipid metabolism into systemic inflammation. For investors, this acquisition underscores Novartis’ commitment to maintaining leadership in high-burden therapeutic areas.
Patients’ Significance
For patients, the acquisition signals renewed hope. Despite advances in lipid management and antithrombotic therapies, millions of ASCVD patients remain at high residual risk due to inflammation. Pacibekitug’s ability to reduce systemic inflammatory markers with convenient once-monthly or once-quarterly dosing could significantly improve patient adherence and outcomes. If successful in Phase 3, this therapy may become the first widely available anti-inflammatory treatment for cardiovascular disease, addressing a decades-long unmet need.
Policy Significance
At the policy level, this acquisition resonates with global health priorities. Cardiovascular disease remains the top driver of healthcare costs and premature deaths, and new therapies that reduce hospitalizations and long-term complications will be attractive to payers and public health systems. Moreover, the potential of pacibekitug to prevent downstream events like heart attacks and strokes could support value-based care models and reimbursement frameworks that favor preventive innovation.
Transaction Highlights
Under the agreement, Novartis will launch a tender offer at USD 48 per share in cash, with completion expected in Q4 2025, pending regulatory and shareholder approvals. Tourmaline will become a wholly owned subsidiary of Novartis following the merger.
This acquisition unites Novartis’ global development capabilities with Tourmaline’s pioneering work in inflammation biology, creating a powerful opportunity to redefine cardiovascular care.
If successful, pacibekitug could reshape ASCVD treatment worldwide, advancing both patient outcomes and the business of cardiovascular innovation.
Source: Novartis Press Release
